BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32022292)

  • 1. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia.
    Sterling C; Webster J
    Am J Hematol; 2020 May; 95(5):529-547. PubMed ID: 32022292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
    Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
    Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
    Hadjis AD; McCurdy SR
    Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
    Murdock HM; Ho VT; Garcia JS
    Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
    Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
    Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches in allogenic transplantation in AML.
    Pei X; Huang X
    Semin Hematol; 2019 Apr; 56(2):147-154. PubMed ID: 30926091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia--recent progress].
    Okamoto S
    Nihon Rinsho; 2009 Oct; 67(10):1944-50. PubMed ID: 19860195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.
    Soiffer RJ
    Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):798-802. PubMed ID: 31431704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.